131 related articles for article (PubMed ID: 16282481)
21. Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.
Perez-Bercoff D; Wurtzer S; Compain S; Benech H; Clavel F
J Virol; 2007 May; 81(9):4540-50. PubMed ID: 17287264
[TBL] [Abstract][Full Text] [Related]
22. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
[TBL] [Abstract][Full Text] [Related]
23. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
24. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 May; 75(10):4832-42. PubMed ID: 11312355
[TBL] [Abstract][Full Text] [Related]
25. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA.
Arts EJ; Marois JP; Gu Z; Le Grice SF; Wainberg MA
J Virol; 1996 Feb; 70(2):712-20. PubMed ID: 8551607
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.
Arion D; Kaushik N; McCormick S; Borkow G; Parniak MA
Biochemistry; 1998 Nov; 37(45):15908-17. PubMed ID: 9843396
[TBL] [Abstract][Full Text] [Related]
27. Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase.
Mavhandu LG; Cheng H; Bor YC; Tebit DM; Hammarskjold ML; Rekosh D; Bessong PO
J Ethnopharmacol; 2020 Aug; 258():112931. PubMed ID: 32360797
[TBL] [Abstract][Full Text] [Related]
28. Identification of HIV-1 reverse transcriptase inhibitors using a scintillation proximity assay.
Van Schoubroeck B; Van Loock M; Ivens T; Dehertogh P; Jochmans D; Dams G
Methods Mol Biol; 2013; 1030():19-24. PubMed ID: 23821257
[TBL] [Abstract][Full Text] [Related]
29. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
de Muys JM; Gourdeau H; Nguyen-Ba N; Taylor DL; Ahmed PS; Mansour T; Locas C; Richard N; Wainberg MA; Rando RF
Antimicrob Agents Chemother; 1999 Aug; 43(8):1835-44. PubMed ID: 10428900
[TBL] [Abstract][Full Text] [Related]
30. The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.
Kew Y; Salomon H; Olsen LR; Wainberg MA; Prasad VR
Antimicrob Agents Chemother; 1996 Jul; 40(7):1711-4. PubMed ID: 8807067
[TBL] [Abstract][Full Text] [Related]
31. Diminished human immunodeficiency virus type 1 reverse transcription and nuclear transport in primary macrophages arrested in early G(1) phase of the cell cycle.
Kootstra NA; Zwart BM; Schuitemaker H
J Virol; 2000 Feb; 74(4):1712-7. PubMed ID: 10644341
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and anti-HIV evaluation of 3'-triazolo nucleosides.
Roy V; Obikhod A; Zhang HW; Coats SJ; Herman BD; Sluis-Cremer N; Agrofoglio LA; Schinazi RF
Nucleosides Nucleotides Nucleic Acids; 2011 Apr; 30(4):264-70. PubMed ID: 21623540
[TBL] [Abstract][Full Text] [Related]
33. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.
Erickson-Viitanen S; Wu JT; Shi G; Unger S; King RW; Fish B; Klabe R; Geleziunas R; Gallagher K; Otto MJ; Schinazi RF
Antivir Chem Chemother; 2003 Jan; 14(1):39-47. PubMed ID: 12790515
[TBL] [Abstract][Full Text] [Related]
34. Nucleotide Sugar Pucker Preference Mitigates Excision by HIV-1 RT.
Yamada K; Wahba AS; Bernatchez JA; Ilina T; Martínez-Montero S; Habibian M; Deleavey GF; Götte M; Parniak MA; Damha MJ
ACS Chem Biol; 2015 Sep; 10(9):2024-33. PubMed ID: 26131619
[TBL] [Abstract][Full Text] [Related]
35. Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions.
Ventura M; Tarrago-Litvak L; Dollé V; Nguyen CH; Legraverend M; Fleury HJ; Litvak S
Arch Virol; 1999; 144(3):513-23. PubMed ID: 10226617
[TBL] [Abstract][Full Text] [Related]
36. The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.
Selmi B; Boretto J; Navarro JM; Sire J; Longhi S; Guerreiro C; Mulard L; Sarfati S; Canard B
J Biol Chem; 2001 Apr; 276(17):13965-74. PubMed ID: 11134027
[TBL] [Abstract][Full Text] [Related]
37. Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
Groschel B; Bushman F
J Virol; 2005 May; 79(9):5695-704. PubMed ID: 15827184
[TBL] [Abstract][Full Text] [Related]
38. Excision of nucleoside analogs from DNA by p53 protein, a potential cellular mechanism of resistance to inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Bakhanashvili M; Novitsky E; Rubinstein E; Levy I; Rahav G
Antimicrob Agents Chemother; 2005 Apr; 49(4):1576-9. PubMed ID: 15793143
[TBL] [Abstract][Full Text] [Related]
39. Intracellular Metabolism of Nucleoside/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse Transcriptase.
Varga A; Lionne C; Roy B
Curr Drug Metab; 2016; 17(3):237-52. PubMed ID: 26651972
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
